Premium
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice
Author(s) -
You Min,
Considine Robert V.,
Leone Teresa C.,
Kelly Daniel P.,
Crabb David W.
Publication year - 2005
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.20821
Subject(s) - adiponectin , endocrinology , medicine , fatty liver , alcoholic fatty liver , lipotoxicity , saturated fatty acid , steatosis , alcoholic liver disease , adipocyte , steatohepatitis , saturated fat , fatty acid , chemistry , biology , insulin resistance , adipose tissue , biochemistry , cholesterol , cirrhosis , disease , insulin
The protective effect of dietary saturated fatty acids against the development of alcoholic liver disease has long been known, but the underlying mechanism is not completely understood. We examined the involvement of the adipocyte hormone adiponectin. Circulating adiponectin levels were significantly elevated by chronic ethanol administration to mice consuming a diet high in saturated fat. The increase in circulating adiponectin was associated with the activation a set of hepatic signaling pathways mediated through AMP‐activated protein kinase, PPAR‐α, and PPAR‐γ coactivator α, which in turn led to markedly increased rates of fatty acid oxidation, prevention of hepatic steatosis, and alleviation of liver enzyme changes. Furthermore, treatment of rat 3T3‐L1 adipocytes with saturated fatty acids (palmitic or stearic acids) in the presence of ethanol increased secretion of adiponectin and enhanced activity of a mouse adiponectin promoter. In conclusion , the protective action of saturated fat against the development of alcoholic fatty liver in mice is partially mediated through induction of adiponectin. The present findings suggest a novel paradigm for dietary fatty acids in the pathogenesis of alcoholic liver disease and provide a promising therapeutic strategy—nutritional modulation of adiponectin—in treating human alcoholic fatty liver disease. (H EPATOLOGY 2005.)